Literature DB >> 19491829

Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.

Anita Gasiorowska1, Tomas Navarro-Rodriguez, Christopher Wendel, Elizabeth Krupinski, Zvi H Perry, Kristina Koenig, Bridget Moty, Jeannette Powers, Ronnie Fass.   

Abstract

OBJECTIVES: The objective of this study was to compare the degree of esophageal acid exposure and duodenogastroesophageal reflux (DGER) during treatment between gastroesophageal reflux disease (GERD) patients who responded fully to proton pump inhibitor (PPI) once a day and those who failed to respond.
METHODS: Gastroesophageal reflux disease patients who continued to report symptoms 3 times a week for 3 months while on PPI once a day were assigned to the PPI failure group. GERD patients who were asymptomatic on PPI once a day for 3 months were assigned to the PPI success group. All patients underwent upper endoscopy to assess esophageal mucosal injury. Subsequently, all patients underwent simultaneous 24-h esophageal Bilitec 2000 and pH testing while on treatment. Patients recorded GERD-related symptoms during the test.
RESULTS: Twenty-four patients were enrolled in the PPI failure group and 23 patients were enrolled in the PPI success group. Endoscopy was normal in 63% of PPI failure patients and 76% of PPI success patients. Abnormal DGER was documented in 82% of PPI success patients vs. 67% of PPI failure patients (P=NS). All pH testing and Bilitec parameters in the PPI failure group were similar to those in the PPI success group (P=NS). Of the 34 GERD symptoms recorded by the PPI failure group, 64% were associated with acid reflux and 41% were associated with DGER (P<0.05).
CONCLUSIONS: There is no difference in the degree of DGER and acid exposure during treatment between patients who failed to respond and those who achieved complete symptom resolution on PPI once daily. GERD symptoms in the PPI failure group are more commonly associated with acid reflux than with DGER.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491829     DOI: 10.1038/ajg.2009.240

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors.

Authors:  Emad Hamdy; Ayman El Nakeeb; Hosam Hamed; Mohamed El Hemaly; Nabil Gad ElHak
Journal:  J Gastrointest Surg       Date:  2014-07-02       Impact factor: 3.452

Review 2.  Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Authors:  Ofer Z Fass; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

Review 3.  Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives.

Authors:  Marzio Frazzoni; Nicola de Bortoli; Leonardo Frazzoni; Salvatore Tolone; Vincenzo Savarino; Edoardo Savarino
Journal:  Dig Dis Sci       Date:  2017-05-26       Impact factor: 3.199

4.  The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?

Authors:  Emmanouela Tsoukali; Daniel Sifrim
Journal:  J Neurogastroenterol Motil       Date:  2010-07-27       Impact factor: 4.924

Review 5.  Cough reflex sensitization from esophagus and nose.

Authors:  Michal Hennel; Mariana Brozmanova; Marian Kollarik
Journal:  Pulm Pharmacol Ther       Date:  2015-10-21       Impact factor: 3.410

Review 6.  Role of non-acid reflux in patients with non-erosive reflux disease.

Authors:  Georgios P Karamanolis; Radu Tutuian
Journal:  Ann Gastroenterol       Date:  2013

7.  The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum.

Authors:  Zilla H Hussain; Emily E Henderson; Carla Maradey-Romerao; Nina George; Ronnie Fass; Brian E Lacy
Journal:  Clin Transl Gastroenterol       Date:  2015-08-13       Impact factor: 4.488

8.  GERD assessment including pH metry predicts a high response rate to PPI standard therapy.

Authors:  Arne Kandulski; Ulrich Peitz; Klaus Mönkemüller; Helmut Neumann; Jochen Weigt; Peter Malfertheiner
Journal:  BMC Gastroenterol       Date:  2013-01-16       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.